CVM Reorg

The Eliquis patient who misses a dose is taking Xarelto. The drugs have the same half life. The once a day was a marketing tool. Eliquis is preferred because it works just as well with less bleeds, especially GI bleeds. It’s about lowering the risk of adverse outcomes…wonder why the more recent Xarelto indications are twice daily dosing.

OK - Should we listen to you - cheerleader - or Duke Clinical Research Institute- who understood your drug apixiban needed BID because of pharmodynamics. Half life is only part of it. This same group also created Rocket the Xarelto study. You child.
 




Do u peoples know how to get a red car out of Wheels? I need red for religious reasons. Thanks
OK - Should we listen to you - cheerleader - or Duke Clinical Research Institute- who understood your drug apixiban needed BID because of pharmodynamics. Half life is only part of it. This same group also created Rocket the Xarelto study. You child.
 




























































Nothing is happening - at least not for reps.
They are hiring vacancies where they can’t move someone from an adjacent territory. Managers need to be reorganized but there are a lot of vacancies, so won’t be many pushed to other TAs. CVM will keep going because Xarelto makes billions and they won’t chance a greater decline by cutting back on sales force. 2024 is safe.
 




The drug has negative sales growth and is losing market share every week. Reps in the top third are there with negative share growth. Top heavy, managers with small teams, WTF is a SQUAD any way, that is a joke. On paper makes sense to double
down on systems but these HSM’s don’t produce any sales and ride on our coattails and do we really need MSL’s and contract MSL’s for a thirteen year old drug. Something needs to change. You socialized Cardiology and Hospital Sales with PCP DM’s and mentalities of busy for busy sake's and this is the result. It needs to happen.